Cargando…

Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease

Background: Mitochondrial dysfunction is observed in chronic kidney disease (CKD). Iron deficiency anaemia (IDA), a common complication in CKD, is associated with poor clinical outcomes affecting mitochondrial function and exacerbating oxidative stress. Intravenous (iv) iron, that is used to treat a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nuhu, Faisal, Seymour, Anne-Marie, Bhandari, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826506/ https://www.ncbi.nlm.nih.gov/pubmed/31640237 http://dx.doi.org/10.3390/antiox8100498

Ejemplares similares

Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia
por: Nuhu, Faisal, et al.
Publicado: (2018)

Measurement of Glutathione as a Tool for Oxidative Stress Studies by High Performance Liquid Chromatography
por: Nuhu, Faisal, et al.
Publicado: (2020)

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial
por: Kassianides, Xenophon, et al.
Publicado: (2022)

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
por: Kassianides, Xenophon, et al.
Publicado: (2021)

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2019)

Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease—A Pooled Analysis
por: Kassianides, Xenophon, et al.
Publicado: (2022)

Correction to: Protocol and baseline data for a prospective open-label explorative randomized singlecenter comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2020)

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
por: Chukwu, Chukwuma A., et al.
Publicado: (2023)

Intravenous Irons: From Basic Science to Clinical Practice
por: Bhandari, Sunil, et al.
Publicado: (2018)

Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease
por: Ho, Hsin-Jung, et al.
Publicado: (2022)

Intravenous Iron Therapy with Saccharated Iron Oxide
por: Deshmukh, P. L.
Publicado: (1952)

A randomized trial of intravenous and oral iron in chronic kidney disease
por: Agarwal, Rajiv, et al.
Publicado: (2015)

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease
por: Granata, Simona, et al.
Publicado: (2009)

Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease
por: Gamboa, Jorge L., et al.
Publicado: (2016)

Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
por: Bhandari, Sunil
Publicado: (2011)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

Safety concerns about intravenous iron therapy in patients with chronic kidney disease
por: Del Vecchio, Lucia, et al.
Publicado: (2016)

Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype
por: Armaly, Zaher, et al.
Publicado: (2015)

Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease
por: Fontecha-Barriuso, Miguel, et al.
Publicado: (2022)

The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease
por: Ng, Jen M., et al.
Publicado: (2010)

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
por: Macdougall, Iain C
Publicado: (2017)

Chronic ethanol consumption induces mitochondrial protein acetylation and oxidative stress in the kidney
por: Harris, Peter S., et al.
Publicado: (2015)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Effect of intravenous iron on endogenous erythropoietin and FGF-23 secretion in patients with chronic kidney disease
por: Muras-Szwedziak, Katarzyna, et al.
Publicado: (2023)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2020)

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
por: Theidel, Ulrike, et al.
Publicado: (2017)

Role of Iron-Related Oxidative Stress and Mitochondrial Dysfunction in Cardiovascular Diseases
por: Yan, Fang, et al.
Publicado: (2022)

Oxidative stress induces mitochondrial iron overload and ferroptotic cell death
por: Chen, Yi, et al.
Publicado: (2023)

Mitochondrial Redox Signaling and Oxidative Stress in Kidney Diseases
por: Aranda-Rivera, Ana Karina, et al.
Publicado: (2021)

Klotho, Oxidative Stress, and Mitochondrial Damage in Kidney Disease
por: Donate-Correa, Javier, et al.
Publicado: (2023)

The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial
por: Greenwood, Sharlene A., et al.
Publicado: (2022)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Intravenous Iron Technique Evaluation in Chronic Heart Failure With Iron Deficiency Anemia
por: Gosavi, Rohit, et al.
Publicado: (2023)

Oxidative Stress in Chronic Kidney Disease
por: Scholze, Alexandra, et al.
Publicado: (2016)

Mitochondrial Reactive Oxygen Species and Their Contribution in Chronic Kidney Disease Progression Through Oxidative Stress
por: Tirichen, Hasna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rc150omtvmufeuv8ikn47o20kd